GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » EBIT

Apures Co (XKRX:149300) EBIT : ₩-4,694.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co EBIT?

Apures Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was ₩-4,694.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-4,694.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Apures Co's annualized ROC % for the quarter that ended in Dec. 2023 was -19.95%. Apures Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Apures Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -20.76%.

Apures Co EBIT Historical Data

The historical data trend for Apures Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co EBIT Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,045.48 -9,963.54 -2,070.23 -4,884.10 -4,693.99

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,045.48 -9,963.54 -2,070.23 -4,884.10 -4,693.99

Competitive Comparison of Apures Co's EBIT

For the Diagnostics & Research subindustry, Apures Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apures Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Apures Co's EV-to-EBIT falls into.


Apures Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-4,694.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apures Co  (XKRX:149300) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Apures Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-4120.25 * ( 1 - -0.02% )/( (23186.023 + 18124.826)/ 2 )
=-4121.07405/20655.4245
=-19.95 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19423.208 - 1280.886 - ( 806.865 - max(0, 6502.12 - 1458.419+806.865))
=23186.023

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15624.916 - 920.423 - ( 980.382 - max(0, 5055.142 - 1634.809+980.382))
=18124.826

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Apures Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4693.985/( ( (17664.508 + max(-2214.877, 0)) + (13795.113 + max(-1024.013, 0)) )/ 2 )
=-4693.985/( ( 17664.508 + 13795.113 )/ 2 )
=-4693.985/15729.8105
=-29.84 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.255 + 455.648 + 134.811) - (1280.886 + 0 + 1582.705)
=-2214.877

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.381 + 359.114 + 36.272) - (920.423 + 0 + 524.357)
=-1024.013

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Apures Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-4693.985/22613.014
=-20.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apures Co EBIT Related Terms

Thank you for viewing the detailed overview of Apures Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Apures Co (XKRX:149300) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » EBIT
Comparable Companies
XKRX:246250 XKRX:086460 XKRX:303360 XKRX:236340 XKRX:109820 XKRX:229000 XKRX:347740 XKRX:031860 XKRX:221800 XKRX:245620 TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Website
http://www.apures.com
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines